Aspirin for Cardiovascular Prevention in Type 2 Diabetes
This paper evaluates whether aspirin should be used for primary prevention of cardiovascular mortality and morbidity in patients with type 2 diabetes. Drawing on pharmacological background, prior clinical literature, and two focused study critiques, the paper argues that aspirin offers limited benefit for diabetic patients who have not yet experienced a cardiovascular event, while posing meaningful risks including gastrointestinal hemorrhage and internal bleeding. The analysis of a Spanish ambulatory care study and a six-year Japanese randomized controlled trial both support the conclusion that low-dose aspirin produces no significant risk reduction in primary prevention for type 2 diabetic patients, and that current prescribing practices may require reassessment.
- Introduction and Drug Overview: Aspirin pharmacology, mechanism, and antiplatelet effect
- Previous Literature on Aspirin and Cardiovascular Prevention: Prior studies on aspirin's benefits and bleeding risks
- Study 1: Aspirin Use in Diabetic Patients in Spain: Spanish ambulatory care study critique and findings
- Study 2: Low-Dose Aspirin for Primary Prevention in Type 2 Diabetes: Japanese RCT on low-dose aspirin in type 2 diabetes
- Conclusion: Aspirin risks outweigh benefits in diabetic primary prevention
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Grounds its argument in pharmacological mechanism first, establishing how aspirin works before evaluating whether that mechanism produces the desired clinical outcomes in diabetic populations.
- Balances a literature review of multiple prior studies with focused critiques of two primary studies, giving readers both broad context and specific analytical depth.
- Consistently weighs benefits against harms, noting that the bleeding risks associated with aspirin may outweigh the modest cardiovascular risk reduction it provides.
Key academic technique demonstrated
The paper demonstrates study critique as an analytical method: for each selected study, the author summarizes the design, sample, and findings before identifying methodological limitations — such as insufficient variance in the Spanish dataset and the absence of a secondary-prevention cohort in the Japanese trial. This two-step summary-then-critique structure is a useful model for evidence-based health science writing.
Structure breakdown
The paper opens with a drug overview and mechanism section, then surveys the broader prior literature on aspirin and cardiovascular outcomes. It moves into focused critiques of two peer-reviewed studies — one observational, one randomized — before closing with a conclusion that synthesizes all evidence into a clear position against routine aspirin use for primary prevention in type 2 diabetic patients.
Introduction and Drug Overview
Should aspirin be used in the primary prevention of cardiovascular mortality and morbidity in patients with type 2 diabetes? Aspirin has long been thought to prevent and reduce the likelihood of cardiovascular disease. However, a growing body of research has shown otherwise. This paper, with the help of selected literature, argues that aspirin cannot reliably play a role in the prevention and reduction of cardiovascular disorders in this population.
Aspirin, also known as acetylsalicylic acid, is a salicylate-based medicine commonly used for the relief of minor pain and aches, and as an antipyretic agent to reduce fever. It was isolated and purified by Felix Hoffmann, a German chemist. Salicylic acid is the main metabolic product of aspirin and has been recognized as an important component of the metabolic systems of both animals and humans. In humans, salicylic acid is considered part of the normal diet, and the synthesis of aspirin occurs in an endogenous manner.1
Aspirin is known to prevent and slow the production of thromboxane — an effect referred to as its antiplatelet action. When blood vessels are damaged, platelets attach to thromboxane, causing a clump of platelets to form on the inner wall of the vessel. These platelet patches can grow into larger masses and may block the vessel entirely. Given this mechanism, aspirin is administered to cardiac patients in low doses to prevent the formation of such platelet aggregations.
References
1. Chan KLF, Jessica YL, Ching MPH, Lawrence CT, Hung MD, Wong VSW, Leung KSV, Kung NN, Hui AJ, Wu JCY, Leung KW, Lee WYV, Lee K, Lee TY, Lau WY, To FK, Chan HLY, Chung S, and Sung JJY. Clopidogrel vs. Aspirin and Esomeprazole to Prevent Recurrent Ulcer Bleeding. N Engl J Med. 2005; 352:238–244.
2. Falk E, and Fernandez-Ortiz A. Role of Thrombosis in Atherosclerosis and Its Complications. American Journal of Cardiology. 1995; 75:5B–11B.
3. Smith CS, Allen J, Blair JN, Bonow O, Brass LM, Fonarow CG, Grundy MS, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak CR, Pearson T, Pfeffer MA, and Taubert KA. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update, Endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006; 113:2363–2372.
4. Keith A. Regulating Information About Aspirin and the Prevention of Heart Attack. The American Economic Review. 1995; 85:96–99.
5. Sicras-Mainar A, Navarro-Artieda R, Rejas-Gutierrez J, Fernandez-de-Bobadilla J, Frias-Garrido X, and Ruiz-Riera R. Use of Aspirin for Primary and Secondary Prevention of Cardiovascular Disease in Diabetic Patients in an Ambulatory Care Setting in Spain. BMC Family Practice. 2007; 8:60.
6. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, and Saito Y. Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes: A Randomized Controlled Trial. JAMA. 2008; 300(18):2134–2141.
Create your account
Always verify citation format against your institution’s current style guide requirements.